Eli Lilly and Company


Eli Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients

Eli Lilly and Company announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults...

NYU Langone Among First to Treat COVID-19 Patients with Novel Antibody Arising out of UBC Spinoff Platform & Rapid Lilly Drug Development

NYU Grossman School of Medicine recently began treating patients in a clinical trial to determine whether an antibody therapy known as LY-CoV555 can safely reduce COVID-19 severity. Sponsored by Eli Lilly and Company, this experimental treatment consists of...

Pin It on Pinterest